PSTU-04 - Accelerating mRNA therapeutics: Vaccines and beyond

Organised by The Australasian Pharmaceutical Science Association


Dr Stuart Newman, Therapeutic Innovation, Australia


The success of the COVID-19 mRNA vaccines has demonstrated the potential of RNA vaccines and therapies. Over the next decade, RNA is poised to become a central therapeutic platform for treating a wide range of human diseases. Accordingly, new RNA vaccines and therapeutics are currently undergoing clinical trials for infectious pathogens, cancer and autoimmunity. This symposium will provide insights into the manufacturing innovations being used to optimise existing RNA vaccine platforms and discuss more broadly, the emerging use of RNA-based strategies in cancer.



11:00 – 11:05 Session introduction by the chair
11:05 – 11:45

Optimising mRNA vaccines — New approaches and innovations

Prof. Colin Pouton, Monash University, Australia

11:45 – 12:25

Accelerating the use of mRNA strategies in cancer

Dr Vi Wickramasinghe, Peter MacCallum Cancer Centre, Australia

12:25 – 12:30 Closing and summary

Learning objectives

  • To describe the processes involved in the development of novel mRNA therapeutics for COVID-19, with a particular focus on emerging strains
  • To appreciate the barriers associated with the clinical implementation of mRNA vaccines on a global scale
  • To identify the novel targets that can be exploited using RNA technology for the treatment of cancer

Take home messages

Learn about the possibilities of mRNA therapeutics for infectious diseases and cancer and the challenges in their translation to the clinic.